Results for the substance capmatinib

Capmatinib is a medication used for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) with mutations in the MET gene. It is a MET kinase inhibitor, which plays a critical role in cancer cell growth and survival.

By blocking MET activity, capmatinib can slow or stop tumor growth and reduce cancer spread. It is particularly used in patients whose tumors have specific mutations that activate the MET pathway.

The medication is taken orally, usually twice daily, as directed by a doctor. Patients need to be closely monitored to assess their response to treatment and manage potential side effects.

Side effects may include nausea, vomiting, fatigue, edema, and changes in liver function. It is important for patients to inform their doctor of any unusual symptoms or adverse reactions.